Brandon Sassouni

I write in support of HB1735 and commend the Committee for considering legislation that advances patient choice, medical innovation, and responsible access to emerging therapies. As an entrepreneur and operator in the regenerative medicine and biotechnology sector, I closely evaluate state policy environments when making decisions about research, clinical operations, and future expansion. States that provide clear, science-aligned frameworks for innovative healthcare delivery are increasingly becoming hubs for high-skill jobs, private investment, and translational medical research. If HB1735 and related measures are enacted, New Hampshire would become a highly attractive jurisdiction for expanding or relocating portions of my operations, including research, clinical development, and supporting technical roles. The bill signals that New Hampshire is open to thoughtful innovation while maintaining appropriate patient safeguards—an approach that is critical for the next generation of medical therapies. Beyond the direct economic impact, legislation like HB1735 helps ensure that patients suffering from serious or chronic conditions have additional pathways to explore treatments under physician supervision, rather than being forced to seek care outside the state or country. I respectfully urge the Committee to support HB1735 and help position New Hampshire as a national leader in forward-looking healthcare policy, biomedical innovation, and patient-centered care. Thank you for your time and consideration.